A Phase 1b Trial of RAY121 in Immunological Diseases

Recruiting Phase 1 NCT06371417

Study Description

A Study Evaluating the Safety and Effectiveness of RAY121 in Patients with Autoimmune Diseases

Study Details

Registry ID:
NCT06371417
Conditions:
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
Phase:
Phase 1
Target Enrollment:
144 participants
Start Date:
Age Range:
18–85 years
Healthy Volunteers:
No

Study Locations (80 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →